Weigh-losing antidiabetic ‘Jardiance’ passed wall of the health insurance

A weight-losing antidiabetic ‘Jardiance’ will receive the health insurance benefits.

According to the industry concerned on the 18^th, Boehringer Ingelheim and Lilly has recently made an agreement for the price of Jardiance(empagliflozin), a SGLT-2 inhibitor. It is expected to be listed in the health insurance registration on April or late May. It is the third application of the benefit among o...